ID   86-2
AC   CVCL_6757
DR   CLO; CLO_0050053
DR   BioSample; SAMN03472011
DR   CGH-DB; 9185-4
DR   Cosmic; 946066
DR   Cosmic; 1048223
DR   Cosmic; 1066157
DR   Cosmic; 1656908
DR   RCB; RCB2134
DR   TKG; TKG 0181
DR   Wikidata; Q54605348
RX   CelloPub=CLPUB00161;
RX   PubMed=7817386;
RX   PubMed=9023415;
RX   PubMed=9538136;
RX   PubMed=15746151;
RX   PubMed=16105816;
RX   PubMed=22313637;
RX   PubMed=38639832;
CC   Population: Japanese.
CC   Doubling time: 1.5 days (CelloPub=CLPUB00161; PubMed=7817386).
CC   HLA typing: A*11:01; B*51:01; C*04:01,15:02 (PubMed=9023415).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): RCB=RCB2134; TKG=TKG 0181
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D13S317: 11
ST   D16S539: 12
ST   D5S818: 11,12
ST   D7S820: 11
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   36Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 18
//
RX   CelloPub=CLPUB00161;
RA   Kobayashi S., Okada S., Inaba H., Syoji W., Hasumi T., Sato N.,
RA   Fujimura S.;
RT   "Culture and growth characteristics of human non-small cell lung
RT   cancer cells.";
RL   Kokenshi 42:73-83(1990).
//
RX   PubMed=7817386; DOI=10.1620/tjem.173.217;
RA   Kobayashi S., Okada S., Yoshida H., Hasumi T., Sato N., Inaba H.,
RA   Nakada T., Fujimura S.;
RT   "Syalil-SSEA1(SLX) levels in supernatant of cultured human lung
RT   carcinoma cell lines.";
RL   Tohoku J. Exp. Med. 173:217-229(1994).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9538136; DOI=10.3892/ijo.12.5.1103;
RA   Takaki T., Hiraki A., Uenaka A., Gomi S., Itoh K., Udono H.,
RA   Shibuya A., Tsuji T., Sekiguchi S., Nakayama E.;
RT   "Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3
RT   peptide recognized by cytotoxic T lymphocytes.";
RL   Int. J. Oncol. 12:1103-1109(1998).
//
RX   PubMed=15746151; DOI=10.1093/hmg/ddi092;
RA   Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in
RT   non-small cell lung cancers.";
RL   Hum. Mol. Genet. 14:997-1007(2005).
//
RX   PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331;
RA   Nagai Y., Miyazawa H., Hu Q., Tanaka T., Udagawa K., Kato M.,
RA   Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.;
RT   "Genetic heterogeneity of the epidermal growth factor receptor in
RT   non-small cell lung cancer cell lines revealed by a rapid and
RT   sensitive detection system, the peptide nucleic acid-locked nucleic
RT   acid PCR clamp.";
RL   Cancer Res. 65:7276-7282(2005).
//
RX   PubMed=22313637; DOI=10.4161/cbt.19238;
RA   Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A.,
RA   Igishi T., Burioka N., Nanba E., Shimizu E.;
RT   "Lack of AKT activation in lung cancer cells with EGFR mutation is a
RT   novel marker of cetuximab sensitivity.";
RL   Cancer Biol. Ther. 13:369-378(2012).
//
RX   PubMed=38639832; DOI=10.1007/s13577-024-01055-0; PMCID=PMC11194210;
RA   Kasai F., Fukushima M., Miyagi Y., Nakamura Y.;
RT   "Genetic diversity among the present Japanese population: evidence
RT   from genotyping of human cell lines established in Japan.";
RL   Hum. Cell 37:944-950(2024).
//